相关实验视频

Updated: May 1, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

精准医学导航器对黑人前列腺癌患者的基因组测试利用的影响

Alexander J Allen¹, Bansi Savla¹, Claudia Datnow-Martinez¹

¹Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.

JCO oncology practice

|March 3, 2026

概括

一个精准医学导航器 (PMN) 增加了包括黑人患者在内的前列腺癌患者的基因组测试率. 然而,与非黑人患者相比,黑人患者的利用率仍然较低,这表明需要进一步研究.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
健康差异在健康上的差异

背景情况:

瘤学中的精准医学依赖于瘤基因组分析.
人们担心基因组测试对代表性不足的群体的访问存在差异,这可能会扩大健康不平等.
精准医学导航员 (PMN) 是一个临床导航员角色,专注于促进瘤基因组测试.

研究的目的:

评估精准医学导航器 (PMN) 是否与前列腺癌患者基因组检测率的增加有关.
确定PMN是否影响黑人患者和其他弱势群体中的基因组测试率.
评估PMN实施后基因组测试利用的潜在差异.

主要方法:

对前列腺癌的回顾性审查在单一医疗保健系统内进行咨询.
基因组测试率在PMN实施前7个月和PMN实施后7个月的比较.
二元逻辑回归分析,以计算接受基因组测试的几率.

主要成果:

基因组测试率从PMN前的18%显著增加到PMN后的70% (P = .0002).
在各种人口群体中观察到测试的增加,包括黑人患者,低收入患者和那些有医疗保险/医疗补助的患者.
尽管总体增加,基因组测试的利用在黑人患者中仍然明显较低 (58.5%) 与非黑人患者相比 (75.4%) 后PMN (P = .0006).

结论:

精准医学导航器 (PMN) 的实施与前列腺癌患者的基因组测试率更高有关.
该PMN显示,对增加黑人患者和其他历史上服务不足的群体的基因组测试产生积极影响.
需要进一步调查,以了解黑人患者在基因组测试利用中的持续差异.

更多相关视频

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...